UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P.H.R. e Big Data. Some juridical considerations about the digital health perspectives

Pharmaceuticals policy and law, 2018-10, Vol.19 (3-4), p.177-195

Donati, Daniele

2018

Volltextzugriff (PDF)

Abstract 4843: NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4843-4843

2018

Volltextzugriff (PDF)

The opinions and feelings about their educational needs and role of familial caregivers of Parkinson’s Disease patients: a qualitative study

Acta bio-medica de l'Ateneo Parmense, 2020-11, Vol.91 (Suppl 12)

2020

Volltextzugriff (PDF)

Stereoselective synthesis of 3,4‐dihydropyrrolopyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Chirality (New York, N.Y.), 2022-11, Vol.34 (11), p.1437-1452

2022

Volltextzugriff (PDF)

Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.805-805

2018

Volltextzugriff (PDF)

Lâ€™errore nella somministrazione di terapia farmacologica endovenosa nelle UnitÃ di Terapia Intensiva: stato dellâ€™arte e strategie

Scenario, 2018-01, Vol.32 (2), p.20-27

2018

Volltextzugriff (PDF)

BRASS score and complex discharge: a pilot study

Acta bio-medica de l'Ateneo Parmense, 2018-01, Vol.88 (4), p.414-425

2018

Volltextzugriff (PDF)

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4785-4785

2018

Volltextzugriff (PDF)

Abstract 4790: Identification and characterization of ATP-mimetic choline kinase inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4790-4790

2019

Volltextzugriff (PDF)

Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1223-1223

2016

Volltextzugriff (PDF)

Abstract 798: NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.798-798

2015

Volltextzugriff (PDF)

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.734-734

2018

Volltextzugriff (PDF)

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5163-5163

2017

Volltextzugriff (PDF)

Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3795-3795

2016

Volltextzugriff (PDF)

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2082-2082

2017

Volltextzugriff (PDF)

Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1638-1638

2015

Volltextzugriff (PDF)

Abstract 2851: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2851-2851

2015

Volltextzugriff (PDF)

Abstract 2097: Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2097-2097

2013

Volltextzugriff (PDF)

Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitor

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A179-A179

2015

Volltextzugriff (PDF)

1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists

Journal of medicinal chemistry, 2007-10, Vol.50 (21), p.5076-5089

2007

Volltextzugriff (PDF)

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2091-2091

2013

Volltextzugriff (PDF)

Abstract 3259: Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3259-3259

2013

Volltextzugriff (PDF)

1 – 25 von 132

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(123)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Animals
(14)
Biological And Medical Sciences
(12)
Humans
(12)
Medical Sciences
(12)
Neuropharmacology
(11)
Neurotransmitters. Neurotransmission. Receptors
(11)
Pharmacology. Drug Treatments
(11)
Rats
(11)
Structure-Activity Relationship
(11)
Male
(7)
Catecholaminergic System
(6)
Receptors, Dopamine D3 - Antagonists & Inhibitors
(6)
Antagonists
(5)
Mice
(5)
Antibiotics
(4)
Dopamine Antagonists - Pharmacology
(4)
Female
(4)
Glutamate
(4)
Glutamatergic System
(4)
Pharmacology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

P.H.R. e Big Data. Some juridical considerations about the digital health perspectives

Abstract 4843: NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma

The opinions and feelings about their educational needs and role of familial caregivers of Parkinson’s Disease patients: a qualitative study

Stereoselective synthesis of 3,4‐dihydropyrrolopyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML

Lâ€™errore nella somministrazione di terapia farmacologica endovenosa nelle UnitÃ di Terapia Intensiva: stato dellâ€™arte e strategie

BRASS score and complex discharge: a pilot study

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

Correction to Discovery of Entrectinib: A New 3‑Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c‑ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Abstract 4790: Identification and characterization of ATP-mimetic choline kinase inhibitors

Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability

Abstract 798: NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models

Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer

Abstract 2851: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1 H -isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

Abstract 2097: Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase

Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitor

1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists

Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT 1A/B/D Receptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4 H -imidazo[5,1- c ][1,4]benzoxazine-3-carboxamide (GSK588045)

Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models

Abstract 3259: Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models

Aktive Filter

Suchergebnisse filtern